Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Tranexamic acid + bacitracin is a combination of two pharmaceutical agents with distinct mechanisms of action. Tranexamic acid is an antifibrinolytic agent that competitively and reversibly inhibits the activation of plasminogen to plasmin, thereby preventing the breakdown of fibrin clots and reducing or preventing hemorrhagic episodes[4][8]. Bacitracin is a cyclic polypeptide antibiotic that interferes with bacterial cell wall synthesis by binding to C55-isoprenyl pyrophosphate, inhibiting its dephosphorylation, which prevents peptidoglycan synthesis in bacteria[1][6]. This combination may be used for local hemostasis and infection prevention in wound care settings.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on tranexamic acid + bacitracin.